Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):815–820. doi: 10.1038/sj.bjc.6690426

Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer

C C Earle 1, W K Evans 1
PMCID: PMC2362269  PMID: 10360660

Abstract

The aim of this study was to assess the cost-effectiveness of combination chemotherapy with paclitaxel/cisplatin, compared with standard etoposide/cisplatin in patients with advanced non-small cell lung cancer (NSCLC). We obtained the primary survival and resource utilization data from a large three-arm randomized trial comparing: paclitaxel 135 mg m−2 by 24-h intravenous (i.v.) infusion + cisplatin; paclitaxel 250 mg m−2 by 24-h i.v. infusion + cisplatin + granulocyte colony-stimulating factor (G-CSF); and standard etoposide/cisplatin in patients with stage IIIb or IV NSCLC. We also modelled the regimens with paclitaxel 135 mg m−2 + cisplatin administered as an outpatient by 3-h infusion, as clinical data suggest that this is equivalent to 24-h infusion. We collected costing data from the Ottawa Regional Cancer Centre and applied it to the resources consumed in the randomized trial. We integrated these data into the Statistics Canada POpulation HEalth Model (POHEM), which generated hypothetical cohorts of patients treated with each regimen. The POHEM model assigned diagnostic work-up, treatment, disease progression and survival characteristics to each individual in these cohorts and tabulated the costs associated with each. We did sensitivity analyses around the costs of chemotherapy and its administration, and the survival differences between the two regimens. All costs are in 1997 Canadian dollars ($1.00 Canadian ~ £0.39 sterling). The perspective is that of the Canadian health care system. In the trial, the two paclitaxel-containing arms had almost identical survival curves with a median survival of 9.7 months compared with 7.4 months for etoposide/cisplatin. As administered in the trial, paclitaxel/cisplatin cost $76 370 per life-year gained (LYG) and paclitaxel/cisplatin/G-CSF $138 578 per LYG relative to etoposide/cisplatin. However, when modelled as an outpatient 3-h infusion, paclitaxel/cisplatin was moderately cost-effective at $30 619 per LYG. When compared with historical controls treated with best supportive care, this regimen of paclitaxel/cisplatin cost $4539 per LYG. Assuming a 3-h paclitaxel infusion yields the same survival advantage as the 24-h infusion did in the randomized trial, paclitaxel/cisplatin is a cost-effective improvement over standard etoposide/cisplatin for patients with advanced non-small cell lung cancer. © 1999 Cancer Research Campaign

Keywords: non-small cell lung cancer, costs, chemotherapy, paclitaxel, cisplatin

Full Text

The Full Text of this article is available as a PDF (84.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberola V., Rosell R., González-Larriba J. L., Molina F., Ayala F., García-Conde J., Benito D., Pérez J. M. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol. 1995;6 (Suppl 3):S49–S52. doi: 10.1093/annonc/6.suppl_3.s49. [DOI] [PubMed] [Google Scholar]
  2. Bonomi P., Kim K., Kusler J., Johnson D. Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer. Oncology (Williston Park) 1997 Apr;11(4 Suppl 3):9–10. [PubMed] [Google Scholar]
  3. Chang A. Y., Kim K., Glick J., Anderson T., Karp D., Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst. 1993 Mar 3;85(5):388–394. doi: 10.1093/jnci/85.5.388. [DOI] [PubMed] [Google Scholar]
  4. Detsky A. S., Naglie I. G. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990 Jul 15;113(2):147–154. doi: 10.7326/0003-4819-113-2-147. [DOI] [PubMed] [Google Scholar]
  5. Earle C. C., Evans W. K. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control. 1997 Oct;1(4):282–288. [PubMed] [Google Scholar]
  6. Evans W. K. An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer. Semin Oncol. 1996 Oct;23(5 Suppl 10):82–89. [PubMed] [Google Scholar]
  7. Evans W. K., Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer. 1996 Dec;32A(13):2249–2255. doi: 10.1016/s0959-8049(96)00298-5. [DOI] [PubMed] [Google Scholar]
  8. Evans W. K., Will B. P., Berthelot J. M., Earle C. C. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol. 1997 Sep;15(9):3038–3048. doi: 10.1200/JCO.1997.15.9.3038. [DOI] [PubMed] [Google Scholar]
  9. Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer. 1995 Nov;72(5):1270–1277. doi: 10.1038/bjc.1995.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol. 1995 Dec;5(4):408–419. [PubMed] [Google Scholar]
  11. Evans W. K., Will B. P., Berthelot J. M., Wolfson M. C. The cost of managing lung cancer in Canada. Oncology (Williston Park) 1995 Nov;9(11 Suppl):147–153. [PubMed] [Google Scholar]
  12. Fossella F. V., Lee J. S., Murphy W. K., Lippman S. M., Calayag M., Pang A., Chasen M., Shin D. M., Glisson B., Benner S. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994 Jun;12(6):1238–1244. doi: 10.1200/JCO.1994.12.6.1238. [DOI] [PubMed] [Google Scholar]
  13. Francis P. A., Rigas J. R., Kris M. G., Pisters K. M., Orazem J. P., Woolley K. J., Heelan R. T. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994 Jun;12(6):1232–1237. doi: 10.1200/JCO.1994.12.6.1232. [DOI] [PubMed] [Google Scholar]
  14. Giaccone G., Splinter T. A., Debruyne C., Kho G. S., Lianes P., van Zandwijk N., Pennucci M. C., Scagliotti G., van Meerbeeck J., van Hoesel Q. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1998 Jun;16(6):2133–2141. doi: 10.1200/JCO.1998.16.6.2133. [DOI] [PubMed] [Google Scholar]
  15. Goss G. D., Dahrouge S., Lochrin C. A. Recent advances in the treatment of non-small cell lung cancer. Anticancer Drugs. 1996 Jun;7(4):363–385. doi: 10.1097/00001813-199606000-00001. [DOI] [PubMed] [Google Scholar]
  16. Jaakkimainen L., Goodwin P. J., Pater J., Warde P., Murray N., Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol. 1990 Aug;8(8):1301–1309. doi: 10.1200/JCO.1990.8.8.1301. [DOI] [PubMed] [Google Scholar]
  17. Laupacis A., Feeny D., Detsky A. S., Tugwell P. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992 Feb 15;146(4):473–481. [PMC free article] [PubMed] [Google Scholar]
  18. Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. doi: 10.1093/jnci/85.5.384. [DOI] [PubMed] [Google Scholar]
  19. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  20. Raby B., Pater J., Mackillop W. J. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol. 1995 Aug;13(8):1904–1911. doi: 10.1200/JCO.1995.13.8.1904. [DOI] [PubMed] [Google Scholar]
  21. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES